Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Tratamento UCon de bexiga hiperativa (OAB) em homens

3 de novembro de 2026 atualizado por: InnoCon Medical

Segurança e desempenho de UCon para gerenciamento de OAB não neurogênico em homens - um estudo de viabilidade inicial

UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The purpose of the current investigation is to obtain information about the type of stimulation that Ucon provide (time limited vs. urge stimulation), would be the most effective and feasible for the treatment of non-neurogenic OAB symptoms in males.

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Maastricht, Holanda
        • Recrutamento
        • Maastricht University Medical Center+
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  1. Subject is ≥ 18 years of age.
  2. Subject is male.
  3. Subject is diagnosed with OAB
  4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.

Exclusion Criteria:

  1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation).

  2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)).

  3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection.

  4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months.

  5. Subject has used antimuscarinics or β3 agonists within 14 days weeks*.

  6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).

  7. Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment.

  8. Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.

  9. Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.

  10. Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.

  11. Subject does not speak and understand Dutch.

    • If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Group A (Urge and Time limited)

The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode.

Participants will receive stimulation for 60 seconds, when they feel an urgency.

Outros nomes:
  • Neuroestimulação
  • Estimulação DGN

Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.

Outros nomes:
  • Neuroestimulação
  • Estimulação DGN
Outro: Group B (Time limited and Urge)

The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the participant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode.

Participants will receive stimulation for 60 seconds, when they feel an urgency.

Outros nomes:
  • Neuroestimulação
  • Estimulação DGN

Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.

Outros nomes:
  • Neuroestimulação
  • Estimulação DGN

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of OAB symptoms in a home setting.
Prazo: After 44 days (end of study)

Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period.

After 44 days (end of study)
PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of OAB symptoms using UCon in a home setting
Prazo: Change from baseline at 14 days, 30 days and 44 days (study end)

Ratio of subjects with at least 50% change in their OAB symptoms from baseline. Participants shall complete a 3-day bladder diary to report their symptoms.

The symptoms related to OAB:

  • Urinary urgency is measured by number of urgency episodes/day.
  • Urinary frequency is measured by number of voidings/day.
  • Urgency urinary incontinence is measured by number of leaks preceded by urgency/day.
  • Nocturia is measured by number of voidings/night.
Change from baseline at 14 days, 30 days and 44 days (study end)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period.
Prazo: After 44 days (end of study)

Number of subjects experiencing adverse events and anticipated adverse device effects. Subjects will report on any experience associated with the use of UCon.

After 44 days (end of study)
SECONDARY SAFETY: To evaluate the severity of adverse events associated with the use of UCon during the investigational period.
Prazo: After 44 days (study end)

Severity of adverse events and anticipated adverse device effects.The severity will be evaluated from the subjects' report on any experience associated with the use of UCon.

After 44 days (study end)
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life.
Prazo: Change from baseline at 14 days and 44 days (end of study)

Ratio of subjects with a change in their OAB quality of life measures as assessed by specific QoL questionnaires related to OAB condition (ICIQ-OAB, AOBq). An overall score with greater values indicates a worse symptom outcome.

Change from baseline at 14 days and 44 days (end of study)
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their treatment outcome (i.e. symptoms) after therapy.
Prazo: Change from baseline at 14 days and 44 days (end of study)

Ratio of subjects with a change in their treatment outcome (i.e. symptoms) assessed by the 7-point Patient Global Impression of Improvement (PGI-I) scale. Higher scores indicates a worse treatment outcome.

Change from baseline at 14 days and 44 days (end of study)
SECONDARY PERFORMANCE: To evaluate the device and treatment acceptability of UCon.
Prazo: After 44 days (study end)

Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period.

After 44 days (study end)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: John Heesakkers, MD, Maastricht UMC+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de outubro de 2023

Conclusão Primária (Estimado)

12 de junho de 2027

Conclusão do estudo (Estimado)

12 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

1 de maio de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de maio de 2023

Primeira postagem (Real)

24 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NL_FEAS_01

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .